Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,659
archived clinical trials in
Metabolic

Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Evans Army Hospital
mi
from
Fort Carson, CO
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Evans Army Hospital
mi
from
Fort Carson, CO
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Children´s Hospital Boston
mi
from
Boston, MA
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Children´s Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Rainbow Babies & Children´s Hospital
mi
from
Cleveland, OH
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Rainbow Babies & Children´s Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
The Children´s Medical Center of Dayton
mi
from
Dayton, OH
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
The Children´s Medical Center of Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Rhode Island Hospital
mi
from
Providence, RI
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Cook Children´s Medical Center
mi
from
Fort Worth, TX
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Cook Children´s Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Texas Children´s Hospital
mi
from
Houston, TX
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Texas Children´s Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
mi
from
Aurora, CO
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
mi
from
New York, NY
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
mi
from
Stony Brook, NY
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
mi
from
Stony Brook, NY
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
mi
from
Seattle, WA
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
mi
from
Philadelphia, PA
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
mi
from
Washington, D.C.,
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Research Site
mi
from
The Bronx, NY
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Research Site
mi
from
The Bronx, NY
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
mi
from
Cleveland, OH
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
mi
from
Kansas City, MO
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
mi
from
Atlanta, GA
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
mi
from
Grand Rapids, MI
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
mi
from
Gent,
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
mi
from
Gent,
Click here to add this to my saved trials
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
Status: Enrolling
Updated:  10/30/2017
University of Arizona Collaboratory for Metabolic Disease Prevention and Treatment
mi
from
Tucson, AZ
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
Status: Enrolling
Updated: 10/30/2017
University of Arizona Collaboratory for Metabolic Disease Prevention and Treatment
mi
from
Tucson, AZ
Click here to add this to my saved trials
Evaluation of Neuroinflammation in Children With Infantile Spasms
Neuroinflammation in Children With Infantile Spasms Measured With 11C-PK11195 Positron Emission Tomography: Response to ACTH
Status: Enrolling
Updated:  11/3/2017
Children's Hospital of Michigan
mi
from
Detroit, MI
Evaluation of Neuroinflammation in Children With Infantile Spasms
Neuroinflammation in Children With Infantile Spasms Measured With 11C-PK11195 Positron Emission Tomography: Response to ACTH
Status: Enrolling
Updated: 11/3/2017
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Status: Enrolling
Updated:  11/8/2017
NYU Langone Medical Center
mi
from
New York, NY
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Status: Enrolling
Updated: 11/8/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Stem Cell Transplant for Inborn Errors of Metabolism
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplant for Inborn Errors of Metabolism
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Stem Cell Transplantation for Hurler
Hematopoietic Stem Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplantation for Hurler
Hematopoietic Stem Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  12/3/2017
University of Minnesota - Fairview
mi
from
Minneapolis, MN
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 12/3/2017
University of Minnesota - Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
Comparative Efficacy of Phenylbutyrate vs. Benzoate in Urea Cycle Disorders
Status: Enrolling
Updated:  12/9/2017
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
Comparative Efficacy of Phenylbutyrate vs. Benzoate in Urea Cycle Disorders
Status: Enrolling
Updated: 12/9/2017
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
New York Medical College
mi
from
Valhalla, NY
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
University of Utah
mi
from
Salt Lake City, UT
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
Childrens Hospital Colorado
mi
from
Denver, CO
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
Childrens Hospital Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders
Status: Enrolling
Updated:  1/9/2018
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders
Status: Enrolling
Updated: 1/9/2018
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Department of Human Genetics, Emory University School of Medicine
mi
from
Atlanta, GA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Department of Human Genetics, Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
University of Iowa Health Clinics
mi
from
Iowa City, IA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
University of Iowa Health Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Duke Univ Med Ctr
mi
from
Durham, NC
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Research Baylor Institute of Metabolic Disease
mi
from
Dallas, TX
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Research Baylor Institute of Metabolic Disease
mi
from
Dallas, TX
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
O&O Alpan
mi
from
Fairfax, VA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
O&O Alpan
mi
from
Fairfax, VA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
The Royal Melbourne Hospital
mi
from
Parkville,
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
The Royal Melbourne Hospital
mi
from
Parkville,
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Orange, CA
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Aurora, CO
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Boston, MA
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Grand Rapids, MI
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Lebanon, NH
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Columbus, OH
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Dayton, OH
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
mi
from
Houston, TX
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials